資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34593
|
| 標題: | Economic evaluation of new blood pressure target for hypertensive patients in Taiwan according to the 2022 hypertension clinical practice guidelines of the Taiwan society of cardiology: a simulation modeling study |
| 作者: | Liao, Chia-Te
Toh, Han Siong
Yang, Chun-Ting
Hsu, Chien-Yi
Lee, Mei-Chuan
Chang, Wei-Ting
Chen, Zhih-Cherng
Chang, Hung-Yu
Strong, Carol |
| 貢獻者: | National Cheng Kung University
Chi Mei Hospital
KU Leuven
Chi Mei Hospital
National Cheng Kung University
Chia Nan University of Pharmacy & Science,Department of Health and Nutrition
National Cheng Kung University
Taipei Medical University
Taipei Medical University
Taipei Medical University
Taipei Medical University
Chi Mei Hospital
Cheng Hsin General Hospital
National Yang Ming Chiao Tung University |
| 關鍵字: | cost-effectiveness
risk
adherence |
| 日期: | 2023 |
| 上傳時間: | 2023-12-11 13:59:36 (UTC+8) |
| 出版者: | SPRINGERNATURE |
| 摘要: | With the promising cardiovascular benefits in the STEP and SPRINT trials, the 2022 Taiwan's hypertension guidelines redefined the hypertension threshold as 130/80 mmHg and a universal blood-pressure target of <130/80 mmHg. This study's objective was to examine the cost-effectiveness of the intensive blood-pressure target for hypertensive patients using estimated lifetime medical costs and quality-adjusted life years (QALY) from the Taiwan national payer's perspective. We developed a lifetime Markov model comparing the intensive and conservative blood-pressure targets. Incremental cost-effectiveness ratio (ICER) against the willing-to-pay thresholds at the one-time [US$34,000(NT$1,020,000)] and three-time [US$100,000(NT$3,000,000)] gross domestic product per capita were defined as very cost-effect and only cost-effective. The cost-effectiveness in different age stratifications and cardiovascular risks treated with a more intensive target (120 mmHg) were examined in the subgroup analyses. The new blood-pressure treatment target produced more lifetime medical costs [US$31,589(NT$947,670) versus US$26,788(NT$803,640)] and QALYs (12.54 versus 12.25), and the ICER was US$16,589(NT$497,670), which was 99.1% and 100% probability of a very cost-effective and cost-effective strategy. The ICERs in all age stratifications had more than a 90% probability of being very cost-effective, and ICERs decreased with age. More intensive control in patients with high cardiovascular risks produced a lower ICER [US$14,547(NT$436,410)]. In conclusion, Taiwan's new blood-pressure treatment target can prevent more cardiovascular events with acceptable costs per QALY below the willing-to-pay thresholds. The cost-effectiveness of intensive control is consistent across different ages and more pronounced with the increase in age and cardiovascular risk. |
| 關聯: | HYPERTENSION RESEARCH, v.46, pp.187–199 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 280 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
